PARIS--(BUSINESS WIRE)--Regulatory News: ExonHit Therapeutics (Paris:ALEHT) (Alternext: ALEHT) announced today that promising new data on EHT 0202, its lead candidate in Alzheimer’s disease (AD), were presented at the 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy from March 24th to March 27th in Geneva, Switzerland.
